Cardiac failure Info desk :Diuretics never save lives, while Dapagliflozin does it in style !
An Interaction in IMCU
How is Mr. K, who was shifted from ward 102 ?
Yes sir, It was acute decompensated LV failure, Patient was in impending pulmonary edema. In fact, he developed. He is fine now,
How did he come around? He was too sick I thought.
“Just pushed 60 mg Frusemide IV, luckily he also had good BP, so with an infusion of NTG, titrated Carvedilol a little bit, he came out nicely. I guess it is Ischemic DCM”.
“Good, You have done a nice job”
“Don’t make me embarrassed sir. It is such a routine in our ER.
To make him curious, I asked “Which drug do you think that s...
Source: Dr.S.Venkatesan MD - December 17, 2021 Category: Cardiology Authors: dr s venkatesan Tags: cardiac failure Cardiology -guidelines cardiology -Therapeutics cardiology wisdom cardiology-ethics Cardiology-Land mark studies Ethics in Medicine evidence based cardiology acc aha esc guidelines on heart failure bumatanide Cardiac fa Source Type: blogs
Cardiac failure Info desk : Diuretics never save lives, while Dapagliflozin does it in style !
An Interaction in IMCU
How is Mr. K, who was shifted from ward 102 ?
Yes sir, It was acute decompensated LV failure, Patient was in impending pulmonary edema. In fact, he developed. He is fine now,
How did he come around? He was too sick I thought.
“Just pushed 60 mg Frusemide IV, luckily he also had good BP, so with an infusion of NTG, titrated Carvedilol a little bit, he came out nicely. I guess it is Ischemic DCM”.
“Good, You have done a nice job”
“Don’t make me embarrassed sir. It is such a routine in our ER.
To make him curious, I asked “Which drug do you think that saved hi...
Source: Dr.S.Venkatesan MD - December 17, 2021 Category: Cardiology Authors: dr s venkatesan Tags: cardiac failure Cardiology -guidelines cardiology -Therapeutics cardiology wisdom cardiology-ethics Cardiology-Land mark studies Ethics in Medicine evidence based cardiology acc aha esc guidelines on heart failure bumatanide Cardiac fa Source Type: blogs
Type 2 diabetes: Which medication is best for me?
If you are living with type 2 diabetes, you certainly are not alone. One in 10 people in the US has diabetes, according to the CDC. However, despite considerable progress in diabetes treatment over the past 20 years, fewer than half of those with diabetes actually reach their target blood sugar goal.
In part, this may be because doctors can be slow to make changes to a patient’s treatment plan, even when a patient’s treatment goals are not being met. One reason for this may be the overwhelming number of medications currently available. And yet, waiting too long to adjust treatment for type 2 diabetes can have long-last...
Source: Harvard Health Blog - November 5, 2020 Category: Consumer Health News Authors: Samar Hafida, MD Tags: Diabetes Drugs and Supplements Source Type: blogs
AZ at it again
AUTH/2793/9/15 - Clinical pharmacist v AstraZenecaCase number:AUTH/2793/9/15Case ref:Clinical pharmacist v AstraZenecaDescription:Identifying patients suitable for Forxiga treatment and failing to provide an accurate response to the PanelNo breach:No breaches Clauses 2 and 7.2Breach:Breaches Clauses 3.2, 7.2 and 9.1. Corrective statement and public reprimand.Appeal:No appealReview:Published in the May 2016 ReviewReceived:10/09/2015Completed:17/03/20162793Case Summary:A clinical pharmacist complained about an AstraZeneca leavepiece about how to create a clinical system search to identify patients suitable for tr...
Source: PharmaGossip - September 28, 2016 Category: Pharmaceuticals Authors: insider Source Type: blogs
MKSAP: 52-year-old woman with type 2 diabetes mellitus
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 52-year-old woman presents for follow-up evaluation after being diagnosed with type 2 diabetes mellitus 6 weeks ago. Her initial HbA1c level was 8.0%. Management at this time is with lifestyle modifications. She has worked closely with a diabetes educator and a nutritionist since her diagnosis. She has lost 3.2 kg (7 lb) by making changes to her diet and activity level. Review of her blood glucose log for the past 2 weeks shows preprandial blood glucose values in the 150 to 160 mg/dL (8.3-8.9 mmol/L) range and...
Source: Kevin, M.D. - Medical Weblog - June 25, 2016 Category: Journals (General) Authors: mksap Tags: Conditions Diabetes Endocrinology Source Type: blogs
FDA Approves New Oral Drug for Type 2 Diabetes
By Diane Fennell
On August 1, the US Food and Drug Administration (FDA) approved the oral diabetes drug Jardiance (generic name empagliflozin) for use, along with a healthful diet and exercise, in adults with Type 2 diabetes. The medicine, a joint development of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, joins Invokana (canagliflozin) and Farxiga (dapagliflozin) as a member of the class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.
In the process of filtering the blood, the kidneys typically reabsorb all the filtered glucose and return it to the bloodstream. One of the main pr...
Source: Diabetes Self-Management - August 8, 2014 Category: Diabetes Authors: Diane Fennell Source Type: blogs
Bristol close to selling diabetes stake to Astra for $3 bln -WSJ
Dec 18 (Reuters) - Bristol-Myers Squibb Co is close to selling its stake in a diabetes partnership with AstraZeneca Plc to the British drugmaker in a deal valued at more than $3 billion, the Wall Street Journal reported on Wednesday.Bristol had announced last month that it would no longer conduct research to discover new drugs for diabetes, hepatitis C and neurological conditions, but would increase spending on medicines that harness the immune system to fight cancer.That refocus led to speculation that Bristol would seek to sell its share in the non-U.S. part of the diabetes joint venture to AstraZeneca.Bristol spokeswoma...
Source: PharmaGossip - December 19, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
AstraZeneca And Bristol-Myers Pull Diabetes Drug From Germany Over Pricing Decision
Once again, drugmakers are at war with the German authorities over pricing. In the latest row, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) have yanked their Forxiga diabetes treatment, which was approved in Europe a year ago, over disagreements about the price of the drug, but will reconsider their decision after arbitration has concluded, according to a statement.
Specifically, the move comes after the drugmakers were unable to reach an agreement with the National Association of Statutory Health Insurance Funds after the German Federal Joint Committee issued a so-called ‘no additional benefit’ rating for the trea...
Source: Pharmalot - December 16, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
For AZ's Onglyza SAVOUR is not a saviour
AstraZeneca has suffered another drug trial setback.
Its diabetes drug Onglyza, developed with Bristol-Myers Squibb, failed to reduce heart risks or strokes in a large scale clinical trial. Despite investor hopes, the Savor trial showed the drug was no better than placebo or standard treatments.
Panmure Gordon analyst Savvas Neophytou issued a hold recommendation on the shares, which have dipped 2.5p to £32.48, saying:
AstraZeneca's eagerly anticipated Savor trial has read out without success in providing a differentiation on cardiovascular risk for diabetes product Onglyza.
This disappointment should be moderat...
Source: PharmaGossip - June 19, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
FDA Approves a Highly Questionable New Diabetes Drug, Invokana
The FDA just gave its approval to the first drug in a new class of diabetes drugs, Johnson & Johnson's canagliflozin, which will be marketed in the U.S. as Invokana.New York Times: FDA Approves a New Diabetes Drug From J.&J. (May require subscription)Reuters: U.S. FDA approves Johnson & Johnson diabetes drug, canagliflozinThis class of drugs, the sodium-glucose co-transporter-2 (SGLT2) inhibitors, lowers blood sugar by blocking reabsorption of glucose by the kidney and increasing its excretion in urine. The manufacturer also claims that it causes weight loss--always a potent selling point for a diabetes drug.As...
Source: Diabetes Update - March 31, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
FDA: Enrichment Strategies to Improve Efficiency of Drug Development
Conclusion
Temple noted that there are some issues with predictive enrichment. One is that you always believe the characteristic you use to enrich predicts the good responders; it may not do this as well as you hope. So it’s very important to characterize the test that leads you to select those patients; then see whether it’s true that patients with the characteristic always (or most of the time) respond, and that patients without the characteristic don’t respond very much.
An issue to consider in any enrichment design is how much you need to study the people who don’t have the enrichment characteristic...
Source: Policy and Medicine - February 12, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
A New J&J Diabetes Pill, Heart Risks & FDA Approval
Another horse race is under way in the diabetes market and Johnson & Johnson is hoping to become the first entrant to sell a treatment known as a SGLT2 inhibitor. The question is whether an unclear cardiovascular risk will prompt the FDA to await final results of a key study, which would delay J&J from selling its drug and intensify the battle.
In advance of an FDA advisory committee meeting this week, agency medical reviewers released a briefing document that noted a concern of high major adverse cardiovascular events during the first 30 days after taking J&J’s canagliflozin in its CANVAS cardiovascul...
Source: Pharmalot - January 8, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized AstraZeneca Avandia Boehringer Ingelheim Bristol Myers Squibb Diabetes Eli Lilly FDA GlaxoSmithKline Januvia JJ Johnson & Johnson Merck Type 2 Diabetes Source Type: blogs
